JMP Securities Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben maintains a Market Outperform rating on Sagimet Biosciences (NASDAQ:SGMT) but lowers the price target from $48 to $32.
August 15, 2024 | 3:39 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JMP Securities maintains a Market Outperform rating on Sagimet Biosciences but lowers the price target from $48 to $32.
The Market Outperform rating suggests continued confidence in Sagimet Biosciences' performance, but the lowered price target indicates tempered expectations for its stock price. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100